



下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡介
MOOC臨床藥學(xué)英語-南京醫(yī)科大學(xué)中國大學(xué)慕課答案單元作業(yè)1單元測試11、問題:Whatwouldyourecommendtothispatientatthistime?選項(xiàng):A、Fulvestrant(氟維司群)aloneB、Fulvestrant+PI3K/AKT/mTORinhibitorinaclinicaltrialC、pan-ErbBreceptorinhibitorinaclinicaltrialD、Chemotherapy正確答案:【Fulvestrant+PI3K/AKT/mTORinhibitorinaclinicaltrial】2、問題:WhydoweneedtolearnClinicalPharmacyEnglish?選項(xiàng):A、IncreaseinternationalmedicalandpharmacyknowledgeB、Improveglobalhealthawarenessandcross-culturalcommunicationabilityC、Broadenstudents’internationalvisionandcultivatestudents’globalcompetenceD、Layfoundationforfollow-upscientificresearch正確答案:【Increaseinternationalmedicalandpharmacyknowledge#Improveglobalhealthawarenessandcross-culturalcommunicationability#Broadenstudents’internationalvisionandcultivatestudents’globalcompetence#Layfoundationforfollow-upscientificresearch】單元作業(yè)2單元測試21、問題:2.Whichoneisfaster,thenormalrateofimpulseinitiationortheSAnode?選項(xiàng):A、impulseinitiationB、theSAnodeC、AVnodeD、same正確答案:【theSAnode】2、問題:HeartTheheartactsasapumpandmaintainscirculationofthebloodbyalternateconcentrationandrelaxationofcardiacmuscle(themyocardium).Itgenerallycontractsatarateof70to75beats/minuteinahealthy70-kgpersonatrest.Thenormalheartrhythm,knownassinusrhythm,originatesinspecializedcardiaccells,calledpacemakercells,inthesino-atrial(SA)orsinusnodeandhasbeendefinedasasinusnoderateof60to100beats/minute.EachheartbeatorcontractionisinitiatedbygenerationofanactionpotentialintheSAnode;theelectricalimpulsespreadsoverbothatria,causingthemtocontract,andontotheatrioventricular(AV)node.FromtheAVnodeitspreadsthroughthebundleofHisanddownthePurkinjefiberstotheventricles,causingthemtocontract.Itisthemovementofionsacrossthecardiaccellmembranethatgeneratestheactionpotential.Theelectricalchangesinvolvedcanberecordedonanelectrocardiogram(ECG).Othercardiaccellsthatarelocatedoutsidethesinusnodearealsocapableofinitiatingimpulses.Thesecells,termedectopicpacemakers,canbefoundintheatriovertricularjunctionandintheHis-Purkinjesystem.Thenormalrateofimpulseinitiationbytheseectopicpacemakersislessthanthatofthesinusnodeandthereforetheydonotnormallyinitiatetheheartbeat.However,theymaybecomedominantincertaincircumstancessuchas:iftheintrinsicrateoftheectopicpacemakerrisesabovethatofthesinusnode;ifthesinusnoderatefallsbelowthatoftheectopicpacemaker;orwhenanormalsinusnodeimpulseispreventedfrombeingconductedthroughtheheart(heartblock)leavingtheectopicpacemakertofireatitsownintrinsicrate.Acardiacarrhythmiacanbedefinedinsimpletermsasanyabnormallyofrate,regularity,orsiteoforiginofthecardiacimpulseorasadisturbanceinconductionthatcausesanabnormalsequenceofactivation.Symptomsdependonthearrhythmiabutmayincludefatigue,dyspnoea,dizziness,andsyncope;suddendeathmayoccur.Palpitationisatermusedtodescribeanunacceptableawarenessofthebeatingheartbythepatient.Thismayoccurnormallyincircumstancessuchasemotion,exercise,orstressormayoccurinassociationwitharrhythmias.Clinically,arrhythmiasmaybeclassifiedbypresumedsiteoforigin,namelyassupraventriculararrhythmias(includingatrialarrhythmiasandatrioventricularjunctionalarrhythmias)orasventriculararrhythmias.Classificationcanalsobebasedonrateaseitherbradyarrhythmias(slow)ortachyarrhythmias(fast).Bradyarrhythmiasarecausedbysinusnodedysfunction,whicheitherdepressesimpulsegenerationordisturbstheconductionofimpulsesfromthesinusnodetotheatria.Atrioventricularblockindicatesdisturbanceofconductionoftheatrialimpulsetotheventricles.Infirst-degreeblocktheimpulseisdelayed.Itisusuallyasymptomaticbutmayprogresstosecond-orthird-degreeblock.Insecond-degreeblocktheimpulseisblockedintermittentlyandinthird-degreeblockthereisacompleteblock.Atrioventriculardissociationindicatesaconditioninwhichventricularactivityisfasterthan,andindependentof,theatrialactivity.Bradyarrhythmiasmaybetreatedwitheitheratropineorisoprenaline,althoughcardiacpacingisthetreatmentofchoice.Fortachyarrhythmiasaclassificationordiagnosisbasedontheprecisemechanismofthearrhythmiawouldalsobedesirablebutthisisnotalwaysclear.Inmanyoftheclinicallyrelevantarrhythmias,however,themechanismisoneofre-entry.Re-entryoccurswhentheinitialimpulsedoesnotdieoutbutcontinuestopropagateandreactivatetheheart.Questions1.OnlytheSAnodecaninitiatetheheartbeat,trueorfalse,why?選項(xiàng):A、正確B、錯(cuò)誤正確答案:【錯(cuò)誤】3、問題:BradyarrhythmiasarecausedbyAVnodedysfunction,trueorfalse?選項(xiàng):A、正確B、錯(cuò)誤正確答案:【錯(cuò)誤】4、問題:Kate’sdoctortoldherthatshemighthasafirst-degreeatrioventricularblockandsuggestedhertotakefurtherexamination.However,Marydoesnotfeelanyuncomfortable.Shouldshetakethedoctor’sadvice?選項(xiàng):A、正確B、錯(cuò)誤正確答案:【正確】單元作業(yè)3單元測試31、問題:HypertensionHypertension,particularlyessentialorprimaryhypertension,iswidespreadandalthoughusuallyasymptomatic,isamajorriskfactorforstrokeandtosomeextentischemicheartdisease.Controlofhypertensionisthereforeamajoraspectofcardiovascularriskreduction.Nationalandinternationalguidelinesonmanagementhavebeenpublished.Definitions:Thetermbloodpressuregenerallymeansarterialbloodpressure,thepressureofthebloodonarterywalls.ItisusuallymeasuredindirectlyinthebrachialarteryjustabovetheelbowusinganappropriatelycalibratedsphygmomanometerandisexpressedinmmHg.Twomeasurementsaremade:systolicormaximumbloodpressure(achievedduringventricularcontractionoftheheart)anddiastolicorminimumbloodpressure(achievedduringventriculardilatation).Hypertensionmeansahigherthan“normal”bloodpressure;ithasbeendefinedasthelevelofbloodpressureabovewhichinterventionhasbeenshowntoreducetheassociatedcardiovascularrisk.Manyfactorsinfluencebloodpressure,resultinginabell-shapeddistributioncurveinthegeneralpopulation,andinconsequenceitisdifficulttodefineanabsolutenorm.Normaladultbloodpressurehasbeenarbitrarilydefinedasasystolicpressurebelow130mmHgtogetherwithadiastolicpressurebelow85mmHg(i.e.below130/85mmHg),butmorerecentstudieshavesuggestedthatoptimalbloodpressure,intermsofcardiovascularrisk,maybelowerthanthis.USguidelinesnowdefinenormalbloodpressureasbelow120/80mmHg,whileEuropeanandBritishguidelinesclassifythisasoptimal.Bloodpressureof130~139/85~89mmHgareregardedashighnormalorareincludedintheclassificationofprehypertension.Althoughhypertensionwasformerlydefinedintermsofdiastolicbloodpressurealone,itisnowrecognizedthatsystolicpressureisalsoimportantindeterminingrisk,andcurrentguidelinesgiveequalemphasistoboth.Bloodpressureabove140mmHgsystolic,and/or90mmHgdiastolicisgenerallyconsideredtorepresenthypertension.Althoughclassificationsofmild,moderate,andseverehypertensionhavebeenwidelyused,thesetermsmaybemisleadingsinceabsolutecardiovascularriskismoreimportantindeterminingtheneedfortreatmentanddependsonotherfactorsinadditiontobloodpressure.Mostguidelinesthereforeuseagradingsystemtoclassifyhypertension,asfollows:grade1:140~159/90~99mmHg;grade2:160~179/100~109mmHg;grade3:≥180/≥110mmHg.IntheUSguidelines,stage1hypertensioncorrespondstograde1,whereasstage2includesbothgrades2and3.Whensystolicanddiastolicpressuresfallintodifferentcategoriesthehighervaluesisusedforclassificationpurposes.Classificationandsubsequenttreatmentdecisionsshouldbebasedonbloodpressuremeasurementstakenonseveraloccasionsoveraperiodthatvariesaccordingtotheseverityofhypertension.Ambulatorybloodpressuremonitoringmaybeusedinsomecases.However,readingstendtobelowerwithambulatorymonitoringthanwithconventionalmeasurementandnormalandabnormalvaluesarenotyetclearlyestablished,althoughrecommendationshavebeenmade.Inmalignantoracceleratedhypertensionrapidlyprogressingseverehypertensionisassociatedwithretinopathyandoftenrenalimpairment.Isolatedsystolichypertensionoccursmainlyintheelderlyandhasbeendefinedassystolicpressureof140mmHgormoreanddiastolicpressureunder90mmHg.1.What’stheshapeofbloodpressuredistribution?選項(xiàng):A、Bell-shapedB、arrow-shapedC、heart-shapedD、linear正確答案:【Bell-shaped】2、問題:Ifthesystolicpressureis144andthediastolicpressureis105,whichgradedoeshypertensioncorrespondto?選項(xiàng):A、Grade1B、Grade2C、Grade3D、Heisnormal正確答案:【Grade2】3、問題:Whichoneusuallyhasalargerreading,ambulatorymonitoringorconventionalmeasurement?選項(xiàng):A、AmbulatorymonitoringB、ConventionalmeasurementC、SameD、Can'tcompare正確答案:【Conventionalmeasurement】4、問題:Allyhasabloodpressureof145/85Hg.Whatisthegivennameforthishypertension?選項(xiàng):A、IsolatedsystolichypertensionB、IsolateddiastolichypertensionC、Grade1D、Grade2正確答案:【Isolatedsystolichypertension】5、問題:Chrishasacardiovascularrelateddisease.Thisyear,hisbloodpressuremeasuredinannualexaminationwas130/85Hg.Hethoughtthattheresultwasveryoptimal.Whatdoyouthinkaboutit,ifyouarehisphysician?選項(xiàng):A、正確B、錯(cuò)誤正確答案:【錯(cuò)誤】單元作業(yè)4單元測試41、問題:PaclitaxelTradeNamesAbraxane-Injection,lyophilizedpowderforsuspension(albuminbound)100mgPaclitaxel-Injection,solution,concentrate6mg/mLApo-PaclitaxelInjectable(Canada)PharmacologyPaclitaxelisanovelantimicrotubuleagentthatpromotestheassemblyofmicrotubulesfromtubulindimersandstabilizesmicrotubulesbypreventingdepolymerization.Thisstabilityinhibitsthenormaldynamicreorganizationofthemicrotubulenetworkthatisessentialforvitalinterphaseandmitoticcellularfunctions.Inaddition,paclitaxelinducesabnormalarraysorbundlesofmicrotubulesthroughoutthecellcycleandmultipleastersofmicrotubulesduringmitosis,furtherdisruptingcellfunction.PharmacokineticsAbsorptionAbraxaneCmaxis18,741ng/mL.PaclitaxelinjectionsolutionFollowing3-and24-hinfusions,Cmaxis195to3,650ng/mLandAUCis6,300to15,007ng?h/mL.Distribution89%to98%proteinbound.Extensiveextravasculardistributionand/ortissuebinding.AbraxaneVdis632L/m2.PaclitaxelinjectionsolutionVdis227to688L/m2atsteadystatewith24-hinfusion.MetabolismPaclitaxelismetabolizedprimarilyto6-alpha-hydroxypaclitaxelbyisoenzymesCYP2C8andto2minormetabolites,3′-p-hydroxypaclitaxeland6-alpha,3′-p-dihyroxypaclitaxelbyCYP3A4.EliminationAbraxaneExcretedintheurine(4%)andinthefeces(20%).Terminalhalf-lifeisapproximately27handtotalbodyClis15L/h/m2.PaclitaxelinjectionsolutionExcretedintheurine(14%)andinthefeces(71%).Following3-and24-hinfusions,thehalf-lifeis13.1to52.7handtotalbodyClis12.2to23.8L/h/m2.SpecialPopulationsRenalFunctionImpairmentTheeffectofrenaldysfunctiononthedispositionofpaclitaxelhasnotbeeninvestigated.HepaticFunctionImpairmentPlasmapaclitaxelexposureisincreased.IndicationsandUsageAbraxaneForthetreatmentofbreastcancerafterfailureofcombinationchemotherapyformetastaticdiseaseorrelapsewithin6moofadjuvantchemotherapy.PaclitaxelinjectionsolutionAsfirst-lineandsubsequenttherapyforthetreatmentofadvancedcarcinomaoftheovary;adjuvanttreatmentofnode-positivebreastcanceradministeredsequentiallytostandarddoxorubicin-containingcombinationchemotherapy;treatmentofbreastcancerafterfailureofcombinationchemotherapyformetastaticdiseaseorrelapsewithin6moofadjuvantchemotherapy;incombinationwithcisplatin,forthefirst-linetreatmentofnon–smallcelllungcancer(NSCLC)inpatientswhoarenotcandidatesforpotentiallycurativesurgeryand/orradiationtherapy;forthesecond-linetreatmentofAIDS-relatedKaposisarcoma.UnlabeledUsesPaclitaxelinjectionsolutionhasbeenusedforsquamouscellheadandneckcancer,smallcelllungcancer,bladdercancer,esophagealcancer,testicularcancer,endometrialcancer,prostatecancer,gastriccancer,germcelltumors,andrefractoryleukemiaandrecurrentWilmstumorinchildren.AbraxanehasbeenusedforNSCLC,metastaticmelanoma,andsquamouscellcancerofthetongue,headandneck,oranalcanal.ContraindicationsHypersensitivityreactionstopaclitaxelorotherdrugsformulatedinCremophorEL(polyoxyethylatedcastoroil)(paclitaxelinjectionsolutiononly);patientswithsolidtumorswhohavebaselineneutrophilcountoffewerthan1,500cells/mm3orinpatientswithAIDS-relatedKaposisarcomawithbaselineneutrophilcountsoflessthan1,000cells/mm3.DosageandAdministrationAbraxaneAdultsBreastcancerIV260mg/m2over30minevery3wk.Forpatientsexperiencingsevereneutropenia(neutrophilcountlessthan500cells/mm3for1wkorlonger)orseveresensoryneuropathy,reducedoseto220mg/m2forsubsequentcourses.Forrecurrenceofsevereneutropeniaorseveresensoryneuropathy,reducedoseto180mg/m2.Forgrade3sensoryneuropathy,holdtreatmentuntilresolutiontograde1or2,andreducethedoseforallsubsequentcoursesoftreatment.PaclitaxelinjectionsolutionAdultsReducedoseby20%forallsubsequentcoursesinpatientswithsevereneuropathyorsevereneutropenia(neutrophilcountlessthan500cells/mm3forlongerthan7days).Questions1)What’sthetradenameforPaclitaxelinCanada?選項(xiàng):A、Apo-PaclitaxelInjec
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 2025-2030年中國白紙板市場發(fā)展趨勢與投資戰(zhàn)略研究報(bào)告
- 貨品分期付款買賣合同
- 信息技術(shù)企業(yè)IT設(shè)備采購合同
- 購物中心租賃合同
- 鋼鐵廠工程施工合同
- 智慧家庭解決方案開發(fā)合同
- 學(xué)校圖書館圖書采購合同
- 工業(yè)品買賣合同范本(33篇)
- 2025年軟件服務(wù)與維護(hù)保養(yǎng)合同范本
- 2025年世界貨物買賣合同范文及實(shí)戰(zhàn)策略
- 2022年鄭州衛(wèi)生健康職業(yè)學(xué)院單招英語模擬試題(附答案解析)
- Q∕GDW 10354-2020 智能電能表功能規(guī)范
- 小學(xué)數(shù)學(xué)四年級下冊培優(yōu)補(bǔ)差記錄
- 人教版三年級下冊體育與健康教案(全冊教學(xué)設(shè)計(jì))
- DB61∕T 5006-2021 人民防空工程標(biāo)識標(biāo)準(zhǔn)
- 土壤學(xué)習(xí)題與答案
- 產(chǎn)品結(jié)構(gòu)設(shè)計(jì)(課堂PPT)
- 第九課_靜止的生命
- 尖尖的東西我不碰(課堂PPT)
- 工程勘察和設(shè)計(jì)承攬業(yè)務(wù)的范圍
- 數(shù)字化影像與PACS教學(xué)大綱
評論
0/150
提交評論